Greater China

Beijing Hyundai Auto Finance and SAIC-GMAC Automotive Finance priced their Chinese auto loan ABS transactions on Tuesday.

Xiaofei Guo has joined Natixis to support the bank’s green and sustainable deal origination and solutions sales in Asia Pacific.

Pharmaron Beijing Co, a pharmaceutical research and development service platform, has launched its Hong Kong SAR flotation, aiming to raise up to HK$4.6bn ($587.8m), said a source familiar with the matter.

China Minmetal’s wholly-owned subsidiary, Onfem Finance, has returned to the market for a HK$4bn ($511m) refinancing loan at tighter levels than its last syndication.

Bank of Shanghai has launched its first sole mandated international loan into general syndication.

Road King Infrastructure returned to the dollar market for the fourth time this year on Monday. The borrower, which has favoured fixed-for-life perpetual bonds before, offered investors a slightly different perpetual deal this time that would see its coupon be reset but has no additional step-up.

Chinese local government financing vehicle Qingdao West Coast Development (Group) Co sold its inaugural offshore bond on Monday, pricing the notes in line with its better-rated peer after an aggressive tightening.

The Securities and Futures Commission of Hong Kong has fined UBS HK$400m ($51m) for overcharging its clients over a 10-year period — in the latest penalty to hit the Swiss bank in the city.

BMW Auto Finance (China) has wrapped up its last foray of the year into the Chinese auto loan ABS market with a tightly priced deal. A diverse group of investors took up the senior tranche of the Rmb8bn ($1.14bn) trade, said bankers.

South African mining company Heaven-Sent Gold Group Co has hit the road to drum up demand from investors for its Hong Kong listing, which could be worth up to HK$1.4bn ($179.8m).

In this round-up, MSCI is set to give a boost to China A-shares again at the end of the month, CPI inflation accelerated to the fastest pace in seven years and the China Securities Regulatory Commission (CSRC) has decided to allow unprofitable companies to list on the ChiNext board.

Chinese biotechnological company Venus Medtech (Hangzhou) is set to launch its Hong Kong IPO, having lined up an international syndicate to run the deal.